DTU researchers pair AI with a photonic quantum computer for cancer vaccine peptides
Researchers at the Technical University of Denmark combined artificial intelligence with a photonic quantum computer to design immune peptides, the short protein fragments that help the immune system recognise diseased or infected cells, in a step toward personalised cancer vaccines. The project is described as a proof-of-concept study and is led by corresponding author Timothy Patrick Jenkins. The Danish team used a photonic quantum computer, which encodes information in individual photons acting as qubits, to broaden how the AI model proposes peptide candidates beyond what a purely classical search would explore.
Laboratory validation of the quantum-designed peptides
The quantum-designed peptides were validated in laboratory experiments, according to the DTU team. The researchers describe the combination of AI and quantum hardware as a potential route to personalised cancer vaccines, though the work remains an early proof-of-concept, with no published human-trial timeline and no peer-reviewed results in patients reported so far.
US Department of Energy selects Mizzou-led team for quantum-integrated synthetic-cell design
The University of Missouri will help lead a US Department of Energy project that integrates quantum methods with artificial intelligence to design synthetic cells for biomanufacturing and biosecurity. The project, titled "Toward a U.S. Institute for Cell Design: AI-Driven Computer-Ready Synthetic Cells with Quantum Integration," is part of the Department of Energy's inaugural Genesis Mission and is led by Roseanna Zia, the Dave Wollersheim Professor of Mechanical and Aerospace Engineering at Mizzou. The team plans to use graph neural networks and other machine-learning approaches for multiscale whole-cell modeling, genome and cell design, and analysis of cryo-electron tomography, visual proteomics, and live-cell imaging data, with the goal of moving synthetic-cell engineering from trial-and-error toward a more predictive design-build-measure-model workflow. Mizzou's proposal was one of 168 university-led projects selected for the mission, which the department describes as combining AI, high-performance computing, and scientific expertise to accelerate discovery across biotechnology and medicine.
What remains uncertain and next steps
Both projects are at early stages. The DTU study is presented as a proof-of-concept, and the authors have not described a clinical pathway, while the Mizzou-led effort is a newly selected DOE project without a published timeline for biomanufacturing or biosecurity deployment. Next verifiable milestones include any peer-reviewed follow-up from the DTU peptide laboratory work and the kickoff of the Mizzou-led team's design-build-measure-model cycle under the Genesis Mission.
Share this article
